EI
DNTH icon

Ethic Inc’s Dianthus Therapeutics DNTH Stock Holding History

Ethic Inc’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
3,265
-35
-1% -$3.06K ﹤0.01% 1100
2026
Q1 		$277K Buy
+3,300
New +$191K ﹤0.01% 1059
2025
Q4 		– Sell
-5,530
Closed -$218K – 1226
2025
Q3 		$218K Buy
+5,530
New +$141K ﹤0.01% 1091

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Ethic Inc's DNTH Position: Q2 2026 in Review

Ethic Inc reduced its Dianthus Therapeutics (DNTH) stake by 1.1% in Q2 2026, selling an estimated $3.06K and leaving 3,265 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

Ethic Inc first reported a position in DNTH in Q3 2025 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Ethic Inc held 3,265 shares of Dianthus Therapeutics worth $318K as of Q2 2026.
  • Ethic Inc sold 35 Dianthus Therapeutics shares in Q2 2026, an estimated $3.06K.
  • Dianthus Therapeutics made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1100 holding.
  • Ethic Inc first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.